In addition to BRCA1, the shRNA screen identified the DNA repair genes ATR and XRCC2 as specific genetic hits in CCNE1-amplified cell lines, suggesting that inhibition of the DDR may be a therapeutic strategy in CCNE1-amplified ovarian cancer. This evidence concerns the gene BRCA1 and ovarian cancer.